02. STRUCTURAL MOLECULAR BIOLOGY

02.1-38 THE STRUCTURE OF GLUCOSE-6-PHOSPHATE ISOMERASE AT 2.6 Å RESOLUTION. A. Achari, S.E. Marshall, H. Muirhead, and P.J. Shaw. Dept. of Biochemistry, University of Bristol, Bristol, BS8 1TD, U.K.

Glucose-6-phosphate isomerase (E.C.5.3.1.9) is the glycolytic enzyme responsible for the interconversion of D-glucose-6-phosphate and D-fructose-6-phosphate. The enzyme from porcine skeletal muscle crystallizes in space group P4_3212, with a = 95.2 Å, c = 138.3 Å. The data for 2.6 Å resolution were collected on a rotation-oscillation camera. An electron density map at a nominal resolution of 2.6 Å has been calculated using phases obtained from isoegenous and anomalous data. Equations 2.5 Å and 2.6 Å resolution were calculated with data from a mercury derivative. The enzyme contains two identical subunits related by a dyad axis. Two distinct domains in each subunit have the G8 type structure (Shaw, P.J. and Muirhead, H., J. Mol. Biol. 109, 675-685, 1977). Sequence information is available for about one third of the molecule from five cyanogen bromide peptides (E.A. Holtman, University of California, Riverside, U.S.A., private communication). A tentative fit of two of these peptides has been made. One of these peptides has a reactive cysteine which has been labelled chemically as a carboxymethyl residue and crystallographically as a mercuorial derivative.

* Current address: John Innes Institute, Norwich, Norfolk, U.K.


The crystal structure of bovine pancreatic ribonuclease-A has been refined by restrained least-squares analysis employing X-ray diffractometer data to 1.45 Å resolution. The current R-factor for 19,238 reflections is 0.25. The mean deviation from ideality of bond lengths is 0.01 Å. Minor corrections to previously reported features of secondary structure are presented and a quantitative analysis of intra molecular hydrogen bonds is given. A total of 79 water or ethanol solvent molecules in the first coordination sphere around the enzyme molecule have been clearly identified and included in the least-squares analysis. A sulphate anion, characterized chemically by laser Raman spectroscopy, and prominently displayed in the 1.45 Å electron density has also been refined as part of the structure. Further new features of the structure to emerge are alternative positions for the active site His-119 side group which have been refined independently with individual occupation factors, a solvent molecule hydrogen bonded to the N-terminal amino group, and disorder of the side chains in the regions of residues 17 to 24 and 35 to 39 neither of which have any structural or biochemical significance for the molecule. Extensive model building by computer graphics has facilitated the production of a sound, accurate model of the ribonuclease-a structure which will now enable detailed and precise analysis of the catalytic mechanism to be undertaken.

02.1-40 THE STRUCTURES OF APO AND HOLO CYTOPLASMIC MALATE DEHYDROGENASE AT HIGH RESOLUTION. By J.J. Birktoft, L.J. Banaszek, and T. Meininger. Department of Biological Chemistry, Washington University School of Medicine, St. Louis, Missouri 63110, U.S.A.

Cytoplasmic malate dehydrogenase (sMDH) crystallizes in one of two nearly isomorphous forms. The appearance of the different unit cells is determined by the presence of the coenzyme NAD and they are thought to contain sMDH in the apo and holo conformational states. A structural comparison at low resolution (5.0 Å) showed that although the overall folding of apo and holo sMDH are rather similar, substantial conformational differences do exist. (Meininger, Birktoft and Banaszek (1977) in "Pyridine Nucleotide-Dependent Dehydrogenases", ed. H. Sund, Walter de Gruyter & Co., p. 87).

In order to further understand these conformational differences as well as to obtain more accurate models, additional diffraction data extending to high resolution have been collected, and constrained crystallographic refinement initiated. Data for holo sMDH at two levels of MAD saturation (60% and 100%) were collected previously by diffractometry, as were the low resolution apo sMDH data. High resolution data, extending to 2.5 Å resolution, for apo sMDH were collected by oscillation photography. A Supper oscillation camera controlled by a microprocessor built and programmed by Drs. R.W. Wrenn and P.H. Bether were used. The "MAC Hod" program package as modified by B. Marshall and ourselves for the PDP 11/34-Optronics P-1000 system were used for the processing of the film data.

The two sets of holo sMDH data (60% holo sMDH and 100% holo sMDH) are to be refined using the Hendrickson-Konnert constrained refinement method. In the absence of a chemically determined amino acid sequence for sMDH, a
tentative "X-ray sequence" has been derived from the 60% holo apo sMDH electron density map. The detailed map interpretation was performed using both a "Richards Box" as well as the MMS-X graphics system. Additionally several peptide fragments as sequenced by Bradshaw and coworkers have been aligned with this X-ray sequence. This sequence alignment was facilitated by the use of a diagonal matching technique, similar to that proposed by McLachlan for amino acid sequence comparisons. It is estimated that approximately 40% of the amino acid residues in holo apo sMDH are correctly assigned at this time.

The original MIR phases were derived for the lattice of the partially substituted holo sMDH. Since apo and holo sMDH are sufficiently isomorphous at low resolution, the phases for holo sMDH can be used for the apo form (Holohan et al., 1971; ts25, 40, 140, 140, 140, 140, 140, 140, 140, 140; space group for both P2_12_1_2). An initial assessment of the structural differences between the two forms have been made at low resolution, and these differences along with absence of NAD will be incorporated into the initial phase calculations for apo sMDH. Through the analysis of successive F- F and 2F- F maps, followed by structural adjustments and recalculation of phases and structure factors a high resolution electron density map for this form for the holo enzyme will finally emerge. This will then provide the starting point for constrained crystallographic refinement of apo sMDH. Progress on this work will be reported and if completed, the molecular structure of apo sMDH will be compared with that of the holo enzyme.

The contributions of Dr. N. Weininger in the collection of low resolution apo sMDH data is gratefully acknowledged. (Supported by NSF Research Grant PCM-792187).

02.1-42 THE MOLECULAR STRUCTURE OF L-3-HYDROXYacyl COENZYME A DEHYDROGENASE. By Hazel M. Holden and Leonard J. Banaszak, Department of Biological Chemistry, Washington University, St. Louis, MO 63110.

L-3-hydroxyacyl Coenzyme A dehydrogenase (RHAD) is a mitochondrial enzyme involved in the ß-oxidation of long chain fatty acids. It is of special structural interest because its catalytic reaction involves binding sites for both CoA and NAD+—RHAD. Furthermore, the enzyme may have a substrate binding site that accommodates the long hydrocarbon chain of the acyl CoA substrate, the length of which varies as the substrate shuttles repeatedly through the ß-oxidation cycle.

Isolated from pig heart, RHAD is known to be a dimer of molecular weight 67,000. The amino acid sequence has recently been established and while a small region in the active site contains several homologous residues, overall there appears to be little homology to other dehydrogenases (Bittar, et al FEBS Letters, 1980). An early monoclinic crystal form obtained from ammonium sulfate was extremely sensitive to unit cell and space group changes in the presence of heavy atom compounds. Crystals obtained from polyethylene glycol in the presence of 0.01 M Tris, pH 8.0, however, proved suitable for an X-ray analysis. These crystals belong to the space group P2_12_1_2 with a=126.3 A, b=82.2 A, and c=124.6 A. Three isomorphous derivatives of RHAD have been prepared using crystals first soaked in an NAD+—containing solution. Again, it was not possible to prepare isomorphous heavy atom derivatives of the apo-enzyme, results that resemble experiences with the earlier monoclinic form.

The positions of the heavy atom sites were determined by inspection of the Patterson maps and confirmed by cross difference Fourier maps. After phase refinement, electron density maps at 7.1 A resolution (3 derivatives) and 5.2 A resolution (2 derivatives) were calculated. The envelopes of the two dimers contained within the asymmetric unit were identified in the low resolution map. The local two-fold symmetry of the RHAD dimer does not seem to be expressed in the binding sites of all of the heavy atom derivatives. However, the results of the rotation function studies and inspection of the electron density maps has led to a tentative solution for the positions of the local two-fold rotation axes.

A difference Fourier map of the apo- and holo-enzyme has also been calculated and indicates the binding of 2 NAD+ molecules per asymmetric unit or one site per dimer. The one site per dimer stoichiometry correlates with some of the heavy atom results. By measuring fluorescence enhancement, equilibrium studies of the binding of NADH to RHAD shows that the coenzyme binding sites in each subunit of the dimer are equivalent (McLaughlin et al, unpublished results). Hence, the one site binding of the NAD observed by X-ray studies is likely to be the result of crystal packing effects. Crystals of RHAD have also been soaked in S-acetoacetyl-pantetheine. Although three-dimensional X-ray data has not yet been measured, preliminary precession photographs suggest that in the presence of S-acetoacetyl-pantetheine, the NAD+ is no longer bound.

Progress on obtaining a high resolution map as well as the methods used to obtain the refined positions of the heavy atom sites, local dyads, and the substrate binding sites will be presented.

Acknowledgements: We are indebted to Tom Weininger for his help in purifying and preparing crystals of s-RHAD and to Dr. Richard Wrenn for his continuing help in maintaining our diffractometer. The work was supported by a grant from the National Science Foundation (PCM 7921864). Hazel M. Holden gratefully acknowledges support from an NIH training grant (GM07067).